Description of Medical ServiceLDR Brachytherapy is the insertion of tiny radioactive capsules or ‘seeds’ into the prostate gland. Generally, 80-120 seeds will be implanted. The radiation from the seeds targets the tumour and destroys the cancerous cells. The seeds are inserted via a hollow needle through the perineum. The procedure is guided by transrectal ultrasound.
Description of Medical ConditionCancer of the prostate gland that is classified as intermediate or high-risk. Intermediate risk prostate cancer is defined as having a Prostate Specific Antigen (PSA) measurement of 10-20 nanograms per millilitre of blood (ng/ml) and/or a Gleason score of 7 and/or a tumour classified as T2b-c. High-risk prostate cancer is classified as having a PSA of greater than 20 and/or a Gleason score of 8-10 and/or a tumour classified as T3 OR 2 or more intermediate risk features.
Reason for ApplicationAmendment to MBS item(s)
Medical Service TypeTherapeutic
Previous Application Number1525
Application FormApplication Form (PDF 1230 KB)
Application Form (Word 162 KB)
Consultation SurveyConsultation Survey (PDF 323 KB)
Consultation Survey (Word 72 KB)
MSAC consultation input must be received by no later than Friday, 10 February 2023 for it to be considered by MSAC at its March 2023 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process